Skip to content
TrialScanner

NCT00215540

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Phase 2TerminatedWINTLead

Registry record

Lead sponsor
Windtree Therapeutics
Conditions
Respiratory Distress Syndrome, Newborn; Premature Birth; Bronchopulmonary Dysplasia
Primary completion
Jul 2006Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00215540 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00215540: SURFAXIN® Treatment for... | TrialScanner